Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2015

Open Access 01-12-2015 | Research

The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?

Authors: Guilherme D Silva, Patrícia SS Lopes, Erich T Fonoff, Rosana L Pagano

Published in: Journal of Neuroinflammation | Issue 1/2015

Login to get access

Abstract

Background

Motor cortex stimulation (MCS) is an effective treatment in neuropathic pain refractory to pharmacological management. However, analgesia is not satisfactorily obtained in one third of patients. Given the importance of understanding the mechanisms to overcome therapeutic limitations, we addressed the question: what mechanisms can explain both MCS effectiveness and refractoriness? Considering the crucial role of spinal neuroimmune activation in neuropathic pain pathophysiology, we hypothesized that modulation of spinal astrocyte and microglia activity is one of the mechanisms of action of MCS.

Methods

Rats with peripheral neuropathy (chronic nerve injury model) underwent MCS and were evaluated with a nociceptive test. Following the test, these animals were divided into two groups: MCS-responsive and MCS-refractory. We also evaluated a group of neuropathic rats not stimulated and a group of sham-operated rats. Some assays included rats with peripheral neuropathy that were treated with AM251 (a cannabinoid antagonist/inverse agonist) or saline before MCS. Finally, we performed immunohistochemical analyses of glial cells (microglia and astrocytes), cytokines (TNF-α and IL-1β), cannabinoid type 2 (CB2), μ-opioid (MOR), and purinergic P2X4 receptors in the dorsal horn of the spinal cord (DHSC).

Findings

MCS reversed mechanical hyperalgesia, inhibited astrocyte and microglial activity, decreased proinflammatory cytokine staining, enhanced CB2 staining, and downregulated P2X4 receptors in the DHSC ipsilateral to sciatic injury. Spinal MOR staining was also inhibited upon MCS. Pre-treatment with AM251 blocked the effects of MCS, including the inhibitory mechanism on cells. Finally, MCS-refractory animals showed similar CB2, but higher P2X4 and MOR staining intensity in the DHSC in comparison to MCS-responsive rats.

Conclusions

These results indicate that MCS induces analgesia through a spinal anti-neuroinflammatory effect and the activation of the cannabinoid and opioid systems via descending inhibitory pathways. As a possible explanation for MCS refractoriness, we propose that CB2 activation is compromised, leading to cannabinoid resistance and consequently to the perpetuation of neuroinflammation and opioid inefficacy.
Appendix
Available only for authorised users
Literature
1.
Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain. 2011;152:2204–5.PubMedCrossRef
2.
3.
4.
5.
Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959–64.PubMedCrossRef
6.
Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. 2010;229:26–50.PubMedCrossRef
7.
Garden G, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol. 2006;1:127–37.PubMedCrossRef
8.
9.
Vallejo R, Tilley DM, Vogel L, Beyamin R. The role of glia and immune system in the development and maintenance of neuropathic pain. Pain Pract. 2010;10:167–84.PubMedCrossRef
10.
Mackie K. Cannabinoid receptors as therapeutic targets. Annu Ver Pharmacol Toxicol. 2006;46:101–22.CrossRef
11.
Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology. 2009;1:244–53.CrossRef
12.
Beggs S, Trang T, Salter M. P2X4R microglia drive neuropathic pain. Nat Neurosci. 2012;15:1068–73.PubMedCrossRef
13.
Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation for the treatment of central pain. Acta Neurochir Suppl. 1991;52:137–9.PubMedCrossRef
14.
Nguyen JP, Lefaucheur JP, Decq P, Uchiyama T, Carpentier A, Fontaine D, et al. Chronic motor cortex stimulation in the treatment of central and neuropathic pain. Correlations between clinical, electrophysiological and anatomical data. Pain. 1999;82:245–51.PubMedCrossRef
15.
Rasche D, Ruppolt M, Stippich C, Unterberg A, Tronnier VM. Motor cortex stimulation for long-term relief of chronic neuropathic pain: a 10 year experience. Pain. 2006;121:43–52.PubMedCrossRef
16.
Cruccu G, Aziz T, Garcia-Larrea L, Hansson P, Jensen T, Lefaucheur J, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14:952–70.PubMedCrossRef
17.
Velasco F, Argüelles C, Carrillo-Ruiz JD, Castro G, Velasco AL, Jiménez F, et al. Efficacy of motor cortex stimulation in the treatment of neuropathic pain: a randomized double-blind trial. J Neurosurg. 2008;108:698–706.PubMedCrossRef
18.
Fontaine D, Hamani C, Lozano A. Efficacy and safety of motor cortex stimulation for chronic neuropathic pain: critical review of the literature. J Neurosurg. 2009;110:251–6.PubMedCrossRef
19.
Fagundes-Pereyra WJ, Teixeira MJ, Reyns N, Touzet G, Dantas S, Blond S. Motor cortex electric stimulation for the treatment of neuropathic pain. Arq Neuropsiquiatr. 2010;68:923–9.PubMedCrossRef
20.
Nguyen JP, Lefaucher JP, Le Guerinel C. Motor cortex stimulation in the treatment of central and neuropathic pain. Arch Med Res. 2000;31:263–5.PubMedCrossRef
21.
Garcia-Larrea L, Peyron R. Motor cortex stimulation for neuropathic pain: from phenomenology to mechanisms. Neuroimage. 2007;37 Suppl 1:S71–9.PubMedCrossRef
22.
Maarrawi J, Peyron R, Mertens P, Costes N, Magnin M, Sindou M, et al. Motor cortex stimulation for pain control induces changes in the endogenous opioid system. Neurology. 2007;69:827–34.PubMedCrossRef
23.
Peyron R, Faillenot I, Mertens P, Laurent B, Garcia-Larrea L. Motor cortex stimulation in neuropathic pain. Correlations between analgesic effect and hemodynamic changes in the brain. A PET study. Neuroimage. 2007;34:310–21.PubMedCrossRef
24.
Fonoff ET, Dale CS, Pagano RL, Paccola CC, Ballester G, Teixeira MJ, et al. Antinociception induced by epidural motor cortex stimulation in naive conscious rats is mediated by the opioid system. Behav Brain Res. 2009;196:63–70.PubMedCrossRef
25.
Viisanen H, Pertovaara A. Roles of the rostroventromedial medulla and the spinal 5-HT(1A) receptor in descending antinociception induced by motor cortex stimulation in the neuropathic rat. Neurosci Lett. 2010;476:133–7.PubMedCrossRef
26.
Pagano RL, Fonoff ET, Dale CS, Ballester G, Teixeira MJ, Britto LR. Motor cortex stimulation inhibits thalamic sensory neurons and enhances activity of PAG neurons: possible pathways for antinociception. Pain. 2012;153:2359–69.PubMedCrossRef
27.
Maarrawi J, Peyron R, Mertens P, Costes N, Magnin M, Sindou M, et al. Brain opioid receptor density predicts motor cortex stimulation efficacy for chronic pain. Pain. 2013;154:2563–8.PubMedCrossRef
28.
Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16:109–10.PubMedCrossRef
29.
Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107.PubMedCrossRef
30.
Fonoff ET, Pereira Jr JP, Camargo LV, Dale CS, Pagano RL, Ballester G, et al. Functional mapping of the motor cortex of rat using transdural electrical stimulation. Behav Brain Res. 2009;202:138–41.PubMedCrossRef
31.
Pagano RL, Assis DV, Clara JA, Alves AS, Dale CS, Teixeira MJ, et al. Transdural motor cortex stimulation reverses neuropathic pain in rats: a profile of neuronal activation. Eur J Pain. 2011;15:268.e1–268.e14.
32.
Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol. 2006;147:281–8.PubMedCentralPubMedCrossRef
33.
Randall LO, Selitto JJ. A method for measurement of analgesic activity of inflamed tissue. Arch Int Pharmacodyn. 1957;111:409–19.PubMed
34.
35.
36.
Smith HS. Activated microglia in nociception. Pain Physician. 2010;13:295–304.PubMed
37.
Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450–5.PubMedCrossRef
38.
Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521–32.PubMedCrossRef
39.
Dai ZK, Lin TC, Liou JC, Cheng KI, Chen JY, Chu LW, et al. Xanthine derivative KMUP-1 reduces inflammation and hyperalgesia in a bilateral chronic constriction injury model by suppressing MAPK and NFκB activation. Mol Pharm. 2014;11:1621–31.PubMedCrossRef
40.
Hu C, Zhang G, Zhao YT. Fucoidan attenuates the existing allodynia and hyperalgesia in a rat model of neuropathic pain. Neurosci Lett. 2014;571:66–71.PubMedCrossRef
41.
Zhou C, Shi X, Huang H, Zhu Y, Wu Y. Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury. Anesth Analg. 2014;118:1090–6.PubMedCrossRef
42.
Lau LT, Yu AC. Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury. J Neurotrauma. 2001;18:351–9.PubMedCrossRef
43.
Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Decosterd I. Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol. 2006;2:259–69.PubMedCentralPubMedCrossRef
44.
45.
46.
Rani Sagar D, Burston JJ, Woodhams SG, Chapman V. Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci. 2012;367:3300–11.PubMedCentralPubMedCrossRef
47.
Luongo L, Maione S, Di Marzo V. Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions. Eur J Neurosci. 2014;39:401–8.PubMedCrossRef
48.
Racz I, Nadal X, Alferink J, Baños JE, Rehnelt J, Martín M, et al. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci. 2008;28:12125–35.PubMedCentralPubMedCrossRef
49.
Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, et al. 1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis. 2010;37:177–85.PubMedCrossRef
50.
New DC, Wong YH. BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett. 2003;536:157–60.PubMedCrossRef
51.
Dossou KS, Devkota KP, Kavanagh PV, Beutler JA, Egan JM, Moaddel R. Development and preliminary validation of a plate-based CB1/CB2 receptor functional assay. Anal Biochem. 2013;437:138–43.PubMedCentralPubMedCrossRef
52.
Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O’Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci. 2003;17:2750–4.PubMedCrossRef
53.
54.
Kao SC, Zhao X, Lee CY, Atianjoh FE, Gauda EB, Yaster M, et al. Absence of μ opioid receptor mRNA expression in astrocytes and microglia of rat spinal cord. Neuroreport. 2012;23:378–84.PubMedCentralPubMedCrossRef
55.
Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia. 2000;29:58–69.PubMedCrossRef
56.
Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia. 2005;49:211–9.PubMedCrossRef
57.
Besson JM, Chaouch A. Peripheral and spinal mechanisms of nociception. Physiol Rev. 1987;67:67–186.PubMed
58.
59.
Trafton JA, Abbadie C, Marek K, Basbaum AI. Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation. J Neurosci. 2000;20:8578–84.PubMed
60.
Smith RR, Martin-Schild S, Kastin AJ, Zadina JE. Decreases in endomorphin-2-like immunoreactivity concomitant with chronic pain after nerve injury. Neuroscience. 2001;105:773–8.PubMedCrossRef
61.
Smith HS. Opioids and neuropathic pain. Pain Physician. 2012;15(3 Suppl):ES93–ES110.PubMed
62.
Truong W, Cheng C, Xu QG, Li XQ, Zochodne DW. Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Ann Neurol. 2003;53:366–75.PubMedCrossRef
63.
64.
Romero-Sandoval A, Nutile-McMenemy N, DeLeo JÁ. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology. 2008;108:722–34.PubMedCentralPubMedCrossRef
65.
Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, et al. Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol. 2011;162:428–40.PubMedCentralPubMedCrossRef
66.
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424:778–83.PubMedCrossRef
67.
Nasu-Tada K, Koizumi S, Tsuda M, Kunifusa E, Inoue K. Possible involvement of increase in spinal fibronectin following peripheral nerve injury in upregulation of microglial P2X4, a key molecule for mechanical allodynia. Glia. 2006;53:769–75.PubMedCrossRef
68.
Lantero A, Tramullas M, Pílar-Cuellar F, Valdizán E, Santillán R, Roques BP, et al. TGF-β and opioid receptor signaling crosstalk results in improvement of endogenous and exogenous opioid analgesia under pathological pain conditions. J Neurosci. 2014;34:5385–95.PubMedCrossRef
69.
Desroches J, Bouchard JF, Gendron L, Beaulieu P. Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience. 2014;261:23–42.PubMedCrossRef
70.
Chiou RJ, Chang CW, Kuo CC. Involvement of the periaqueductal gray in the effect of motor cortex stimulation. Brain Res. 2013;1500:28–35.PubMedCrossRef
71.
Senapati AK, Huntington PJ, Peng YB. Spinal dorsal horn neuron response to mechanical stimuli is decreased by electrical stimulation of the primary motor cortex. Brain Res. 2005;1036:173–9.PubMedCrossRef
Metadata
Title
The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?
Authors
Guilherme D Silva
Patrícia SS Lopes
Erich T Fonoff
Rosana L Pagano
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2015
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-014-0216-1

Other articles of this Issue 1/2015

Journal of Neuroinflammation 1/2015 Go to the issue

Research

Suppression of MAPK attenuates neuronal cell death induced by activated glia-conditioned medium in alpha-synuclein overexpressing SH-SY5Y cells

Research

Ligand engagement of Toll-like receptors regulates their expression in cortical microglia and astrocytes

Research

Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation

Research

Transcription factor myocyte enhancer factor 2D regulates interleukin-10 production in microglia to protect neuronal cells from inflammation-induced death

Research

Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury

Erratum

Erratum to: Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains